# A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia

> **NCT00261573** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 593 (actual)

## Conditions studied

- Alzheimer Disease
- Vascular Dementia

## Interventions

- **DRUG:** galantamine hydrobromide

## Key facts

- **NCT ID:** NCT00261573
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-12
- **Primary completion:** —
- **Final completion:** 2000-12
- **Target enrollment:** 593 (ACTUAL)
- **Last updated:** 2011-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00261573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00261573, "A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00261573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*